ciclomed logo.png
CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium
13 févr. 2020 09h15 HE | CicloMed LLC
First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...